Next Article in Journal
#Nomask on Instagram: Exploring Visual Representations of the Antisocial Norm on Social Media
Next Article in Special Issue
Lifestyle, Physical Activity and Dietary Habits of Medical Students of Wroclaw Medical University during the COVID-19 Pandemic
Previous Article in Journal
Effects of Different Types of High-Intensity Interval Training (HIIT) on Endurance and Strength Parameters in Children and Adolescents
Previous Article in Special Issue
Consequences of the SARS-CoV-2 Infection on Anaerobic Performances in Young Elite Soccer Players
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Estimated Oxygen Consumption with the Abbreviated Method and Its Association with Vaccination and PCR Tests for COVID-19 from Socio-Demographic, Anthropometric, Lifestyle, and Morbidity Outcomes in Chilean Adults

by
Jaime Vásquez-Gómez
1,2,
César Faúndez-Casanova
2,3,
Ricardo Souza de Carvalho
2,3,
Franklin Castillo-Retamal
2,3,
Pedro Valenzuela Reyes
4,
Yeny Concha-Cisternas
5,6,
Pablo Luna-Villouta
7,8,
Cristian Álvarez
9,
Andrés Godoy-Cumillaf
10,
Claudio Hernández-Mosqueira
11,
Igor Cigarroa
12,
Alex Garrido-Méndez
13,
Carlos Matus-Castillo
13,
Marcelo Castillo-Retamal
2,3,* and
Ivana Leao Ribeiro
14,15,*
1
Centro de Investigación de Estudios Avanzados del Maule (CIEAM), Universidad Católica del Maule, Talca 3460000, Chile
2
Laboratorio de Rendimiento Humano, Universidad Católica del Maule, Talca 3460000, Chile
3
Departamento de Ciencias de la Actividad Física, Facultad de Ciencias de la Educación, Universidad Católica del Maule, Talca 3460000, Chile
4
Área de Actividad Física y Deportes, Técnico en Deportes, Centro de Formación Técnica Santo Tomás, Rancagua 2820000, Chile
5
Escuela de Kinesiología, Facultad de Salud, Universidad Santo Tomás, Talca 3460000, Chile
6
Pedagogía en Educación Física, Facultad de Educación, Universidad Autónoma de Chile, Talca 3460000, Chile
7
Facultad de Educación, Pedagogía en Educación Física, Universidad San Sebastián, Concepcion 4030000, Chile
8
Programa de Doctorado en Ciencias de la Actividad Física, Facultad de Ciencias de la Educación, Universidad Católica del Maule, Talca 3460000, Chile
9
Exercise and Rehabilitation Sciences Laboratory, School of Physical Therapy, Faculty of Rehabilitation Sciences, Universidad Andres Bello, Santiago 7591538, Chile
10
Facultad de Educación, Pedagogía en Educación Física, Universidad Autónoma de Chile, Temuco 4780000, Chile
11
Departamento de Educación Física, Deportes y Recreación, Universidad de La Frontera, Temuco 4780000, Chile
12
Escuela de Kinesiología, Facultad de Salud, Universidad Santo Tomás, Los Angeles 4440000, Chile
13
Departamento de Ciencias del Deporte y Acondicionamiento Físico, Universidad Católica de la Santísima Concepcion, Concepcion 4030000, Chile
14
Departamento de Kinesiología, Facultad de Ciencias de la Salud, Universidad Católica del Maule, Talca 3460000, Chile
15
Escuela de Ciencias del Deporte y Actividad Física, Facultad de Salud, Universidad Santo Tomás, Talca 3460000, Chile
*
Authors to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2022, 19(11), 6856; https://doi.org/10.3390/ijerph19116856
Submission received: 10 March 2022 / Revised: 24 May 2022 / Accepted: 30 May 2022 / Published: 3 June 2022
(This article belongs to the Special Issue Sport, Physical Activity and Health at Time of COVID-19)

Abstract

:
COVID-19 causes cardiovascular and lung problems that can be aggravated by confinement, but the practice of physical activity (PA) could lessen these effects. The objective of this study was to evaluate the association of maximum oxygen consumption ( V ˙ O2max) with vaccination and PCR tests in apparently healthy Chilean adults. An observational and cross-sectional study was performed, in which 557 people from south-central Chile participated, who answered an online questionnaire on the control of COVID-19, demographic data, lifestyles, and diagnosis of non-communicable diseases. V ˙ O2max was estimated with an abbreviated method. With respect to the unvaccinated, those who received the first (OR:0.52 [CI:0.29;0.95], p = 0.019) and second vaccine (OR:0.33 [CI:0.18;0.59], p = 0.0001) were less likely to have an increased V ˙ O2max. The first vaccine was inversely associated with V ˙ O2max (mL/kg/min) (β:−1.68 [CI:−3.06; −0.3], p = 0.017), adjusted for BMI (β:−1.37 [CI:−2.71; −0.03], p = 0.044) and by demographic variables (β:−1.82 [CI:−3.18; −0.46], p = 0.009); similarly occur for the second vaccine (β: between −2.54 and −3.44, p < 0.001) on models with and without adjustment. Having taken a PCR test was not significantly associated with V ˙ O2max (mL/kg/min). It is concluded that vaccination significantly decreased V ˙ O2max, although it did not indicate cause and effect. There is little evidence of this interaction, although the results suggest an association, since V ˙ O2max could prevent and attenuate the contagion symptoms and effects.

1. Introduction

As in other countries of the world, Chile is carrying out the control process of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus), also called COVID-19 (Coronavirus Disease), regarding the taking of PCR (Polymerase Chain Tests Reaction) and vaccination. On the one hand, the positivity of the PCR test has been less than 3% in the country, with about 1375 new cases daily and almost 51,000 tests administered in mid-December 2021 [1]. On the other hand, and the same date, the population that received the first two doses of the vaccine has exceeded 90% at the national level [2], and in the central-southern macro zone of Chile (regions of O’Higgins, Maule, Ñuble, and Biobío) [3], more than 90% of people over 18 years of age have had two doses of the vaccine [4]. These figures are being updated weekly by the pertinent institutions of the Republic of Chile mentioned recently.
It has been suggested that the coronavirus family carries respiratory diseases that include various symptoms [5] and that the SARS virus (Severe Acute Respiratory Syndrome), which is the predecessor of the current COVID-19, compromises the cardiovascular system, causing some alterations [6], and decreases the ability to perform physical exercise [7]. This COVID-19 virus causes cardiovascular problems [6,8] with respiratory symptoms after an acute period of contagion [8] and after several months of contracting the virus [9], with limitations on the performance of exercise physical in the post-hospitalization phase [10]. Even cardiovascular disorders due to COVID-19 have been linked to hospitalization and death [8]. Specifically, this virus activates signals in a cascade that produce inflammation at the lung level. It also causes mitochondrial dysfunction, which decreases its biogenesis, reduces immunity, ATP resynthesis, and increases oxygen reactive substances such as free radicals [11], although it has been postulated that the regular practice of PA acts inversely on these phenomena produced by COVID-19 [11], reducing the effects of viral infections, systemic inflammation [12,13], the risk of hospitalization, admission to the intensive care unit, and death from COVID-19 [13]. However, sanitary confinement measures have gone against PA [8,14], since there has been a decrease in the time allocated to its practice, causing a decrease in strength, muscle mass, and cardiorespiratory fitness (CRF) [15], including chronic stress that affects mental health [16]. Confinement could lead to increases in sedentary lifestyle [8], which can also affect body adiposity and CRF [14], which in long periods of rest has progressively reduced V ˙ O2max in young adults [17]. It has even been postulated that a sedentary life increases the probability of death due to the virus [12]. The practice of PA and the development of CRF is relevant due to the repercussions on risk factors and the immune system [18]; therefore, it is necessary to apply cardiopulmonary stress tests for clinical and clinical research control [8].
One of the ways to evaluate CRF is through abbreviated methods that use demographic data, body adiposity, lifestyles, and cardiometabolic diseases, but predict CRF without performing physical exercise [19]. Several studies have used abbreviated methods over time that have been validated in different demographic contexts and with varied morpho-functional characteristics and life habits of the population [20,21,22,23,24,25,26,27]. As these become relevant and feasible for larger-scale population research due to their simplicity, low cost, time, supplies, trained personnel, etc., especially in during the current pandemic, where sanitary restrictions make it very difficult to collect empirical data, and evaluation through direct methods (gold standard) or field tests are not feasible [19]. The appearance of COVID-19 has brought with it elements to which societies have had to adapt quickly. Because of the pandemic, it has been necessary for public health bodies to generate evidence on the variables that could influence the contagion and the variables of PA. In turn, the results of this can be transferred to the Chilean health system and materialize from primary care to tertiary care. Governments can establish guidelines for PA during the pandemic period [28], ensure necessary PA counseling in diverse health centers [29] and that popular PA programs are implemented [30], to complement the methods of prevention and treatment of the virus and its current variants. The importance of active participation of the population in adherence to the PA practice should also be taken into account.
There has been a scarce evaluation of CRF as well as other aspects of physical fitness studies in population before the COVID-19 pandemic [18], the relevance of the evaluation of cardiopulmonary function [8], and a higher CRF has been associated with a lower risk of positivity in the PCR test [31]. Thus, data need to be collected and given practical use in an eventual “post pandemic” stage. The objective of this research was to evaluate the association of V ˙ O2max with vaccination and PCR tests against COVID-19 according to socio-demographic variables in apparently healthy people over 18 years of age in the central-southern macro zone of Chile.

2. Materials and Methods

This was a cross-sectional observational study based on the recommendations of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement [32] with a non-random and convenience sample (non-probabilistic/purposive sampling) that was captured through virtual social networks (massive messages by WhatsApp (Meta Platforms, Inc., Menlo Park, CA, USA, [email protected]), Instagram (Meta Platforms, Inc., San Francisco, CA, USA, [email protected]). Participants who consented to give their personal information had to complete a one-time online self-report questionnaire, which was applied between May and August 2021. They were asked to give their consent, declare if they were 18 years old or older, and if they reside in one of the four regions of the central-southern macro zone of Chile: O’Higgins, Maule, Ñuble, and Biobío. If someone did not meet the inclusion criteria, the questionnaire was automatically closed without the participant being able to complete it; therefore, duplicated answers were not possible, avoiding selection bias. The final sample was made up of 557 participants of Chilean nationality (54% women) aged 28.9 ± 9.7 years (Figure 1).
The study was approved by a scientific ethics committee and all participants gave their virtual consent to access the questionnaire anonymously, in compliance with Law No. 19,628 of the Republic of Chile, regarding the protection of personal data. The online questionnaire was guided by the International Ethical Guidelines for Health-Related Research with Human Beings on the “Use of data obtained in online environments and digital tools in health-related research” and “Research in disaster situations and disease outbreaks”, both prepared by the Council for International Organizations of Medical Sciences [33] in collaboration with the World Health Organization.
The Google Forms platform was used for the questionnaire, in which anthropometric data (weight, height, and BMI [body mass index] [34]) were collected. Ad hoc questions were used to obtain information on inoculation against COVID-19 (first and second vaccines: SINOVAC, PFIZER, CANSINO, ASTRAZENECA), performances and results of any PCR test, demographic data (sex, age, area of residence, educational level, marital status, and occupational situation), information on lifestyle habit, walking pace, monthly PA and sitting time, and diagnosis of metabolic diseases (hypertension, diabetes, high cholesterol, heart attack, vascular accident, or cerebral thrombosis) [35]. The V ˙ O2max was estimated in absolute terms (L/min) using an abbreviated method through the variables of body weight, age, and sex [26,36,37] and it was transformed to its relative form (mL/kg/min) by multiplying the absolute value by 1000 mL; this product was divided into body weight [38]. The relative form of V ˙ O2max was classified according to sex and age [39] into two categories: “very low, low, or normal” or “good, excellent, or superior”.
The data were presented in mean values and standard deviation, which were subjected to a Kolmogorov–Smirnov normality test, and the variables between both sexes were compared with a Student’s t-test or Kruskal–Wallis test, as appropriate. In addition, the categorical variables were presented as absolute and relative values, and the prevalence was determined according to the sex of the participants with the chi-square test (x2) or Fisher’s exact test. The continuous and categorical variables were accompanied by their respective confidence intervals (95% CI). Finally, it was evaluated to what extent COVID-19 control influenced V ˙ O2max; for this, the increase or decrease in oxygen consumption associated with vaccination and the PCR test was evaluated through the probability odds ratio (OR) calculation, and using linear regression with the beta (β) coefficient accompanied by unadjusted regression models adjusted for BMI, demographic variables, lifestyle variables, and the diagnosis of cardiometabolic diseases. All the analysis was carried out with the STATA v.14 program considering statistical significance with a p-value < 0.05 (38 cases that had erroneous and/or incomplete records were not part of the analysis, in addition, 10 cases that decided not to participate in the study, leaving a total of 557 participants).

3. Results

Table 1 shows the characteristics of the sample. It was observed that there were differences between men and women in V ˙ O2max, either in absolute or relative terms, and that this variable was categorized as “low, very low, or normal” in a high percentage (~80%), both in men as in women, although there was no prevalence by either of the two sexes. It was also noted that a high percentage of respondents reported having been vaccinated against COVID-19 with the first (~80%, between January and July 2021) and second dose (~70%, between February and August 2021). The SINOVAC brand (CoronaVac) was the one with the highest application (58% of the total) and significant differences in prevalence were found between men and women. Regarding the PCR test, 57.3% of the total participants underwent this preventive and diagnostic test, with there being differences by sex, and the “negative” result was the one with the highest percentage (~90%). Finally, lifestyle habits such as sitting time, walking pace, and PA practice showed differences between men and women, while the diagnosis of metabolic and cardiovascular diseases had a low percentage (~1 to 20%). The prevalence of diabetes was significantly marked by sex, which could be attributed to the fact that most of the participants were young adults.
People who were vaccinated against COVID-19, either with the first or second dose, were significantly less likely (48 and 67%, respectively) to have a higher V ˙ O2max compared to people who were not vaccinated. For their part, those who underwent the PCR test were less likely to have better oxygen consumption compared to those who did not undergo the test. Those who obtained a positive result on the PCR test were more likely to have a higher V ˙ O2max compared to those that obtained a negative result, although the latter results were not statistically significant (Table 2).
Table 3 and Table 4 show the control variables for COVID-19, of which some of them were able to predict V ˙ O2max. In Table 3, no variable was significantly associated with absolute oxygen consumption (L/min), except for the model adjusted for BMI (β: −0.24 [CI: −0.37; −0.11], p < 0.001), in which all had a negative interaction. The effect of being vaccinated for the first or second time, performing a PCR test, and having a negative result in the latter decreased the V ˙ O2max. For its part, for oxygen consumption in relative terms, the first vaccine decreased it by −1.68 mL/kg/min in the unadjusted model: by −1.37 mL/kg/min when adjusted for BMI and by −1.82 mL/kg/min when adjusted for demographic variables. The second dose of the vaccine had significant associations with a decrease in V ˙ O2max (β between −2.54 and −3.44 mL/kg/min) in the unadjusted model and all the adjusted models (Table 4).

4. Discussion

The most important result of this research was that vaccination against COVID-19 had an inverse association with V ˙ O2max. People who had received first and second doses had a decrease in their CRF compared to those who did not vaccinate. In this association variables of body adiposity, demographics, lifestyles, and diagnosis of cardiometabolic diseases intervened. It has been suggested that a small change in V ˙ O2max could limit the risk of contagion [40] and that it would be expected that the CRF would decrease during the acute stage of COVID-19 infection [8]. Accordingly, we suggest as a hypothesis that the vaccine produced an acute effect of lowering V ˙ O2max since the people who reported having been vaccinated were inoculated with the COVID-19 virus itself. We can support this hypothesis based on the findings of Batatinha et al. [41], who, when applying a pre-test, vaccine (Pfizer and Johnson&Johnson), and post-test, did not find significant differences in V ˙ O2max on a cycle ergometer between the two measurements, both in infected, non-infected (both vaccinated), and control participants (not vaccinated), although the sample was only 12 participants.
We can also hypothesize that the same subjects who reported have been vaccinated in the present study perceived a diminished state of health. For that reason, they went to health centers to be vaccinated, due to being motivated by confinement [8,14], fear and possibly misinformation about the pandemic [16], decreased practice of PA and physical fitness [15], changes in body fat [14], and increases in sedentary lifestyle [8]. It should be considered that so far, there have been no reports regarding the impact of the vaccine (SINOVAC, for example, which was the most reported in this research) on V ˙ O2max, since there is a knowledge gap to corroborate what reports our results.
The comparative evidence indicates that lung capacity and volume were significantly protective variables of severe symptoms due to COVID-19 (relative risk (RR) < 1.0; p < 0.05). Moreover, “fast” walking speed was a significant protective variable of excess body adiposity, reflected by the BMI, while conversely, having a “slow” walking pace was a risk factor [42]. Another study reinforced this result on gait speed, reporting that subjects who walked at a moderate intensity reduced the probability of hospitalization due to COVID-19 by 64% (OR: 0.36 [CI: 0.13; 0.98], p = 0.04) compared to those who walked slowly [43], so a slow walking pace can be a predictor of serious contagion by COVID-19 [44]. These findings could explain our results, since among participants who declared that they had received the first vaccine, and when this was adjusted for BMI, a negative and significant association was demonstrated with the relative V ˙ O2max (Table 4).Being vaccinated a second time was inversely associated with oxygen consumption, both absolute (Table 3) and relative (Table 4). The model that considered the second vaccination and that was adjusted for lifestyle variables, which included walking pace or speed, also showed an inverse and significant association with relative oxygen consumption (Table 4). This is in opposition to previous literature. Previous research has also reported that age, bodyweight loss, being an active smoker, and length of hospitalization for COVID-19 were negatively and significantly associated with the prediction of V ˙ O2max [7]. Although our results demonstrated that only the second dose of the vaccine was negatively associated with V ˙ O2max when it was adjusted for lifestyle habits, among them the smoking habit (Table 4).
The evidence regarding the PCR test is still limited. One study has shown that people with a “moderate” (RR: 0.93 [CI: 0.72; 1.21]) or “high” CRF (RR: 0.77 [CI: 0.52; 1.15]) had a lower relative risk of positivity in the said test compared to those who had a low CRF level, although not significantly [31]. On the contrary, our results indicated that the positivity of the PCR test was associated with a greater probability of increasing V ˙ O2max, although this was not statistically significant either (Table 2).
It has been suggested that non-serious, hospitalized patients with COVID-19 have had a lower V ˙ O2max at 3 months after discharge or convalescence [8]. At the same time, it has also been found that the probability of hospitalization for COVID-19 was higher in patients who had lower CRF, and, conversely, it was lower in people with a higher level of fitness, so lower CRF was 2.88 times more likely to be hospitalized (OR: 3.88 [CI: 1.78; 8.77]) [45]. These same researchers also demonstrated that the probability of hospitalization was lower in those younger than 65 years compared to those older this age, in non-obese than in obese, and in men than in women, although there were no significant differences between any of them. Some chronic pathologies, such as diabetes, kidney disease, coronary arteries, heart failure, cancer, and hypertension, had a significant association (OR: from 1.95 to 5.39; p < 0.05) with the probability of hospitalization due to COVID-19, but when these variables were adjusted by CRF, five of these pathologies were no longer associated [46]. It has even been shown that after 4 months of follow-up, for patients hospitalized for COVID-19, those who were on mechanical ventilation showed significantly less cardiopulmonary capacity (p < 0.05) and shorter predicted distance (p < 0.05) in the 6-min walk test compared to patients that did not require ventilation [47]. The distance in the walk test was also significantly lower in patients who were hospitalized compared to control subjects [48]. A prospective study has shown that subjects with “medium” and especially “high” CRF had significantly lower probabilities of hospitalization due to COVID-19 (OR: 0.76 [CI: 0.67; 0.85]), admission to the intensive care unit (OR: 0.61 [CI: 0.48; 0.78]), and mortality due to the virus (OR: 0.56 [CI: 0.37; 0.85]) compared to subjects with a low CRF level [18]. In this last and delicate aspect, a low CRF also resulted in a significantly 134% higher risk of mortality from COVID-19 (RR: 2.34 [CI: 1.35; 4.05]) when compared to moderate- or high-level fitness [31]. It has also been found that patients who were hospitalized for COVID-19 had significantly lower V ˙ O2max in a cycle ergometer test, compared to control subjects [48] and that mechanically ventilated patients had limited exercise capacity due to the decrease in lung capacity and peripheral muscle mass [49]. Our research did not include questions about the hospitalization that the respondents may have had, which could be considered sensitive information and perceived as invasive; moreover, access to these records is restricted and they belong to patients and health centers managed by the Republic of Chile. However, it is pertinent to demonstrate and discuss the importance of V ˙ O2max concerning hospitalization, due to the implications that it may have in terms of prevention and possible treatment of the sequelae of COVID-19.
Finally, the critical literature expresses that V ˙ O2max should be considered a variable of vital signs [8,40], at the beginning of the clinical evaluation, together with demographic and other data, since COVID-19 has challenged us to think about complementary forms of evaluation. Considering that a small increase in V ˙ O2max is likely to have benefits in the body, and can serve to discriminate between patients with higher and lower risk of contagion [40]. For its part, regarding the evaluation of V ˙ O2max through stress tests, it is necessary to apply them during the virus contagion stage to obtain more information about these tests and how they could help control COVID-19. Since to date, there are no specific records of stress tests for this virus [10] from they have been carried out on very small samples [41]. On the other hand, it is known that the development of aerobic exercise of moderate or intense intensity increases lymphocytes and other immune cells in the blood [5]; therefore, one of the utilities that the evaluation of CRF status could have in the young adult age is that it could influence the severity of COVID-19 many years later [18]. There is even evidence that has shown significant decreases in V ˙ O2max before and after an outbreak of COVID-19 in young convalescents, and at the same time, a statistically lower V ˙ O2max compared to newly infected and asymptomatic individuals [50]. The development of the CRF could materialize with popular PA programs that aim to improve public health [30].
A strength of this research is that this was a pioneering study in Chile on V ˙ O2max and the control of COVID-19, in which V ˙ O2max was evaluated through an abbreviated method, this being a novel and viable methodology to use in times of sanitary restriction and confinement measures. It highlights the contribution of the abbreviated methods for predicting V ˙ O2max, encouraging this variable to be included in the clinical evaluation due to the implication it may have on COVID-19, and the prevalence in public health on chronic communicable and non-chronic diseases. Another strength is that this study was carried out in a context where the vaccination process has had coverage by a high percentage of the population. One limitation is that a self-report questionnaire was used, which could lead to participants underestimating or overestimating their responses. This condition was also described as a limitation in population studies where questionnaires and self-reports have been used [51,52]. However, questionnaires are instruments that have been used frequently to collect information during the pandemic in many places in the world [53,54], including Chile [52,55], to apply as a digital tool in disaster and disease outbreak conditions [33]. Finally, it should be considered that this was an observational cross-sectional study; thus, the results of the association between the V ˙ O2max/control variables of COVID-19 did not indicate cause and effect, which is supported by other research that has used a cross-sectional design [52,56,57]. Future research could attempt to associate V ˙ O2max with the hospitalization stage, in the first instance through self-reported data, by improving the questionnaire applied in this study, and later by accessing data released by health institutions, both private and public. Moreover, future papers should stimulate the development of the CRF by calculating the MET (metabolic equivalent of task), since these variables are linked to each other, and the CRF is associated with health outcomes (i.e., adiposity, lifestyles, and cardiometabolic diseases) [25].

5. Conclusions

It is concluded that vaccination against COVID-19 significantly decreased the chances of increasing the V ˙ O2max of the participants. A decrease in absolute V ˙ O2max (L/min) was influenced by variables such as BMI. A decrease in V ˙ O2max in relative terms (mL/kg/min) was influenced by BMI, demographic variables, life habits, and diagnosis of non-transmissible diseases. The second vaccine had significant associations in the unadjusted model, as well as all the adjusted models. The PCR examination was not significantly associated with V ˙ O2max. None of these associations demonstrated cause and effect.

Author Contributions

Conceptualization, J.V.-G., C.Á., A.G.-C., I.C., M.C.-R. and I.L.R.; methodology, J.V.-G., C.Á., A.G.-C., I.C., M.C.-R. and I.L.R.; software, J.V.-G., C.F.-C., R.S.d.C., F.C.-R., M.C.-R. and I.L.R.; formal analysis, J.V.-G., M.C.-R. and I.L.R.; investigation, J.V.-G., P.V.R., Y.C.-C., P.L.-V., A.G.-M., C.H.-M. and C.M.-C.; writing—original draft preparation, J.V.-G., C.F.-C., R.S.d.C., F.C.-R., M.C.-R. and I.L.R.; writing—review and editing, all authors; supervision, J.V.-G., C.F.-C., R.S.d.C., F.C.-R., P.V.R., Y.C.-C., P.L.-V., A.G.-M., C.H.-M., C.M.-C., M.C.-R. and I.L.R.; project administration, J.V.-G., M.C.-R. and I.L.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Comité de Ética Científico de la Universidad Santo Tomás, Chile (protocol code n° 24–21; 10 May 2021).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ministerio de Salud. Available online: https://www.minsal.cl/ (accessed on 22 October 2021).
  2. Ministerio de Salud. Available online: https://www.gob.cl/yomevacuno/#vacunados (accessed on 22 October 2021).
  3. Agencia Nacional de Investigación y Desarrollo. Available online: https://ayuda.anid.cl/hc/es/articles/360048066052--Cuáles-son-las-Macrozonas-del-Ministerio-de-Ciencia-Tecnología-Conocimiento-e-Innovación- (accessed on 22 October 2021).
  4. Ministerio de Salud. Available online: https://informesdeis.minsal.cl/SASVisualAnalytics/?reportUri=%2Freports%2Freports%2F9037e283-1278-422c-84c4-16e42a7026c8&sectionIndex=1&sso_guest=true&sas-welcome=false (accessed on 22 October 2021).
  5. Phansopkar, P.A.; Naqvi, W.M.; Sahu, A.I. COVID-19 pandemic- a curse to the physical well-being of every individual in lock-down. J. Evol. Med. Dent. Sci. 2020, 9, 2561–2566. [Google Scholar] [CrossRef]
  6. Zheng, Y.; Ma, Y.; Zhang, J.; Xie, X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020, 7, 259–260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Clavario, P.; De Marzo, V.; Lotti, R.; Barbara, C.; Porcile, A.; Russo, C.; Beccaria, F.; Bonavia, M.; Bottaro, L.C.; Caltabellotta, M.; et al. Assessment of functional capacity with cardiopulmonary exercise testing in non-severe COVID-19 patients at three months follow-up. ERJ Open Res. 2020, 7, 3. [Google Scholar] [CrossRef]
  8. Mihalick, V.; Canada, J.; Arena, R.; Abbate, A.; Kirkman, D. Cardiopulmonary exercise testing during the COVID-19 pandemic. Prog. Cardiovasc. Dis. 2021, 67, 35–39. [Google Scholar] [CrossRef] [PubMed]
  9. Fraser, E. Long term respiratory complications of COVID-19. BMJ (Clin. Res. Ed.) 2020, 370, m3001. [Google Scholar] [CrossRef]
  10. Faghy, M.; Sylvester, K.; Cooper, B.; Hull, J. Cardiopulmonary exercise testing in the COVID-19 endemic phase. Br. J. Anaesth. 2020, 125, 447–449. [Google Scholar] [CrossRef]
  11. Burtscher, J.; Millet, G.; MBurtscher, M. Low cardiorespiratory and mitochondrial fitness as risk factors in viral infections: Implications for COVID-19. Br. J. Sport. Med. 2021, 55, 413–415. [Google Scholar] [CrossRef]
  12. Salgado-Aranda, R.; Pérez-Castellano, N.; Núñez-Gil, I.; Orozco, A.J.; Torres-Esquivel, N.; Flores-Soler, J.; Chamaisse-Akari, A.; Mclnerney, A.; Vergara-Uzcategui, C.; Wang, L.; et al. Influence of baseline physical activity as a modifying factor on COVID-19 mortality: A single-center, retrospective study. Infect. Dis. Ther. 2021, 10, 801–814. [Google Scholar] [CrossRef]
  13. Sallis, R.; Young, D.R.; Tartof, S.Y.; Sallis, J.F.; Sall, J.; Li, Q.; Smith, G.N.; Cohen, D.A. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: A study in 48 440 adult patients. Br. J. Sport. Med. 2021, 55, 1099–1105. [Google Scholar] [CrossRef]
  14. Jarnig, G.; Jaunig, J.; van Poppel, M. Association of COVID-19 mitigation measures with changes in cardiorespiratory fitness and body mass index among children aged 7 to 10 years in Austria. JAMA Netw. Open 2021, 4, e2121675. [Google Scholar] [CrossRef]
  15. Conceição, M.S.; Derchain, S.; Vechin, F.C.; Telles, G.; Maginador, G.F.; Sarian, L.O.; Libardi, C.A.; Ugrinowitsch, C. Maintenance of muscle mass and cardiorespiratory fitness to cancer patients during COVID-19 era and after SARS-CoV-2 vaccine. Front. Physiol. 2021, 12, e655955. [Google Scholar] [CrossRef] [PubMed]
  16. Burtscher, J.; Burtscher, M.; Millet, G.P. (Indoor) isolation, stress, and physical inactivity: Vicious circles accelerated by COVID-19? Scand. J. Med. Sci. Sport. 2020, 30, 1544–1545. [Google Scholar] [CrossRef]
  17. López-Bueno, R.; Calatayud, J.; Andersen, L.L.; Casaña, J.; Ezzatvar, Y.; Casajús, J.A.; López-Sánchez, G.F.; Smith, L. Cardiorespiratory fitness in adolescents before and after the COVID-19 confinement: A prospective cohort study. Eur. J. Pediatr. 2021, 180, 2287–2293. [Google Scholar] [CrossRef] [PubMed]
  18. Geijerstam, A.A.; Mehlig, K.; Börjesson, M.; Robertson, J.; Nyberg, J.; Adiels, M.; Rosengren, A.; Åberg, M.; Lissner, L. Fitness, strength and severity of COVID-19: A prospective register study of 1 559 187 Swedish conscripts. BMJ Open 2021, 11, e051316. [Google Scholar] [CrossRef]
  19. Vásquez-Gómez, J.A.; Garrido-Méndez, A.; Matus-Castillo, C.; Poblete-Valderrama, F.; Díaz-Martínez, X.; Concha-Cisternas, Y.; Cigarroa, I.; Martorell, M.; Martínez-Sanguinetti, M.A.; Leiva-Ordoñez, A.M.; et al. Fitness cardiorrespiratorio estimado mediante ecuación y su caracterización sociodemográfica en población chilena: Resultados de la encuesta nacional de salud 2016-2017. Rev. Med. Chil. 2020, 148, 1750–1758. [Google Scholar] [CrossRef]
  20. Jackson, A.; Blair, S.; Mahar, M.; Wier, L.; Ross, R.; Stuteville, J. Prediction of functional aerobic capacity without exercise testing. Med. Sci. Sport. Exerc. 1990, 22, 863–870. [Google Scholar] [CrossRef] [PubMed]
  21. Sloan, R.A.; Haaland, B.A.; Leung, C.; Padmanabhan, U.; Koh, H.C.; Zee, A. Cross-validation of a non-exercise measure for cardiorespiratory fitness in Singaporean adults. Singap. Med. J. 2013, 54, 576–580. [Google Scholar] [CrossRef] [Green Version]
  22. Cáceres, J.; Ulbrich, A.; Panigas, T.; Benetti, M. Equações de predição da aptidão cardiorrespiratória de adultos sem teste de exercícios físicos. Rev. Bras. Cineantropom. Desempenho. Hum. 2012, 14, 287–295. [Google Scholar] [CrossRef] [Green Version]
  23. Jang, T.; Park, S.; Kim, H.; Kim, J.; Hong, Y.; Kim, B. Estimation of maximal oxygen uptake without exercise testing in Korean healthy adult workers. Tohoku. J. Exp. Med. 2012, 227, 313–319. [Google Scholar] [CrossRef]
  24. Schembre, S.; Riebe, D. Non-exercise estimation of VO(2)max using the international physical activity questionnaire. Meas. Phys. Educ. Exerc. Sci. 2011, 15, 168–181. [Google Scholar] [CrossRef] [Green Version]
  25. Peterman, J.E.; Harber, M.P.; Imboden, M.T.; Whaley, M.H.; Fleenor, B.S.; Myers, J.; Arena, R.; Finch, W.H.; Kaminsky, L.A. Accuracy of nonexercise prediction equations for assessing longitudinal changes to cardiorespiratory fitness in apparently healthy adults: BALL ST cohort. J. Am. Heart Assoc. 2020, 9, e015117. [Google Scholar] [CrossRef] [PubMed]
  26. de Souza e Silva, C.G.; Kaminsky, L.A.; Arena, R.; Christle, J.W.; Araújo, C.G.S.; Lima, R.M.; Ashley, E.A.; Myers, J. A Reference equation for maximal aerobic power for treadmill and cycle ergometer exercise testing: Analysis from the FRIEND registry. Eur. J. Prev. Cardiol. 2018, 25, 742–750. [Google Scholar] [CrossRef] [PubMed]
  27. Myers, J.; Kaminsky, L.; Lima, R.; Christle, J.; Ashley, E.; Arena, R. A reference equation for normal standards for VO 2 max: Analysis from the fitness registry and the importance of exercise national database (FRIEND Registry). Prog. Cardiovasc. Dis. 2017, 60, 21–29. [Google Scholar] [CrossRef] [PubMed]
  28. Ministerio de Desarrollo Social y Familia. Available online: http://eligevivirsano.gob.cl/noticias/autoridades-detallaron-alcances-de-banda-horaria-elige-vivir-sano-que-rige-desde-hoy/ (accessed on 5 March 2022).
  29. Salinas, C.J.; Bello, S.S.; Chamorro, R.H.; Gonzalez, C.G. Consejeria en alimentación, actividad fÍsica y tabaco: Instrumento fundamental en la practica profesional. Rev. Chil. Nutr. 2016, 43, 434–442. [Google Scholar] [CrossRef] [Green Version]
  30. Kosmas, I.; Georgiou, Y.; Marmara, E.; Fotiou, A. Sociodemographic factors and low back pain in municipality physical activity programs for female participants. Phys. Educ. Sport. 2020, 18, 447–456. [Google Scholar] [CrossRef]
  31. Christensen, R.; Arneja, J.; St Cyr, K.; Sturrock, S.; Brooks, J. The association of estimated cardiorespiratory fitness with COVID-19 incidence and mortality: A cohort study. PLoS ONE 2021, 16, e0250508. [Google Scholar] [CrossRef]
  32. Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007, 370, 1453–1457. [Google Scholar] [CrossRef]
  33. Consejo de Organizaciones Internacionales de las Ciencias Médicas. Available online: https://cioms.ch/wp-content/uploads/2017/12/CIOMS-EthicalGuideline_SP_INTERIOR-FINAL.pdf (accessed on 22 October 2021).
  34. Kosmas, J.; Georgiou, Y.; Marmara, E.; Fotiou, A. Evaluation of municipal fitness programs for women with low back pain. J. Anthr. Sport. Phys. Educ. 2019, 3, 33–39. [Google Scholar] [CrossRef]
  35. Ministerio de Salud. Available online: http://web.minsal.cl/wp-content/uploads/2017/11/ENS-2016-17_PRIMEROS-RESULTADOS.pdf (accessed on 5 July 2021).
  36. Wasserman, K.; Hansen, J.E.; Sue, D.Y.; Stringer, W.W.; Whipp, B.J. Principles of Exercise Testing and Interpretation, 5th ed.; Lippincott, Williams & Wilkins: Baltimore, MD, USA, 2011. [Google Scholar]
  37. Pistea, C.; Lonsdorfer, E.; Doutreleau, S.; Oswald, M.; Enache, I.; Charloux, A. Maximal aerobic capacity in ageing subjects: Actual measurements versus predicted values. ERJ Open. Res. 2016, 2, e00068. [Google Scholar] [CrossRef] [Green Version]
  38. Wilmore, J.; Costill, D. Introducción a la Fisiología del Esfuerzo y del Deporte, 6th ed.; Editorial Paidotribo: Barcelona, Spain, 2007. [Google Scholar]
  39. Loópez Chicharro, J.; Fernaández Vaquero, A. Fisiologiía del Ejercicio, 3rd ed.; Meédica Panamericana: Madrid, Spain, 2006. [Google Scholar]
  40. Ahmed, I. COVID-19–Does exercise prescription and maximal oxygen uptake (VO2 max) have a role in risk-stratifying patients? Clin. Med. 2020, 20, 282–284. [Google Scholar] [CrossRef]
  41. Batatinha, H.A.P.; Baker, F.L.; Smith, K.A.; Zuñiga, T.M.; Pedlar, C.R.; Burgess, S.C.; Katsanis, E.; Simpson, R.J. Recent COVID-19 vaccination is associated with modest increases in the physiological demands to graded exercise. medRxiv 2021, 1–15. [Google Scholar] [CrossRef]
  42. Celis-Morales, C.; Salas-Bravo, C.; Yáñez, A.; Castillo, M. Inactividad física y sedentarismo. La otra cara de los efectos secundarios de la Pandemia de COVID-19. Rev. Med. Chile 2020, 148, 881–886. [Google Scholar] [CrossRef]
  43. Brandenburg, J.; Lesser, I.; Thomson, C.; Giles, L. Does higher self-reported cardiorespiratory fitness reduce the odds of hospitalization from COVID-19? J. Phys. Act. Health 2021, 18, 782–788. [Google Scholar] [CrossRef]
  44. Yates, T.; Razieh, C.; Zaccardi, F.; Rowlands, A.V.; Seidu, S.; Davies, M.; Khunti, K. Walking pace and risk of severe COVID-19 and mortality: Analysis of UK Biobank. Int. J. Obes. 2021, 45, 1155–1159. [Google Scholar] [CrossRef] [PubMed]
  45. Brawner, C.A.; Ehrman, J.K.; Bole, S.; Kerrigan, D.J.; Parikh, S.S.; Lewis, B.K.; Gindi, R.M.; Keteyian, C.; Abdul-Nour, K.; Keteyian, S.J. Inverse relationship of maximal exercise capacity to hospitalization secondary to coronavirus disease 2019. Mayo. Clin. Proc. 2021, 96, 32–39. [Google Scholar] [CrossRef] [PubMed]
  46. Kerrigan, D.; Brawner, C.; Ehrman, J.; Keteyian, S. Cardiorespiratory fitness attenuates the impact of risk factors associated with COVID-19 hospitalization. Mayo Clin. Proc. 2021, 96, 822–823. [Google Scholar] [CrossRef]
  47. Labarca, G.; Henríquez-Beltrán, M.; Lastra, J.; Enos, D.; Llerena, F.; Cigarroa, I.; Lamperti, L.; Ormazabal, V.; Ramirez, C.; Espejo, E.; et al. Analysis of clinical symptoms, radiological changes and pulmonary function data 4 months after COVID-19. Clin. Respir. J. 2021, 15, 992–1002. [Google Scholar] [CrossRef] [PubMed]
  48. Raman, B.; Cassar, M.P.; Tunnicliffe, E.M.; Filippini, N.; Griffanti, L.; Alfaro-Almagro, F.; Okell, T.; Sheerin, F.; Xie, C.; Mahmod, M.; et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine 2021, 31, e100683. [Google Scholar] [CrossRef] [PubMed]
  49. Blokland, I.J.; Ilbrink, S.; Houdijk, H.; Dijkstra, J.-W.; Bennekom, C.A.M.V.; Fickert, R.; De Lijster, R.; Groot, F.P. Exercise capacity after mechanical ventilation because of COVID-19: Cardiopulmonary exercise tests in clinical rehabilitation. Ned. Tijdschr. Geneeskd. 2020, 164, e5253. [Google Scholar]
  50. Crameri, G.A.G.; Bielecki, M.; Züst, R.; Buehrer, T.W.; Stanga, Z.; Deuel, J.W. Reduced maximal aerobic capacity after COVID-19 in young adult recruits, Switzerland, May 2020. Eurosurveillance 2020, 25, e2001542. [Google Scholar] [CrossRef]
  51. Vásquez-Gómez, J.A.; Beltrán, A.R.; Cigarroa-Cuevas, I.; Lasserre-Laso, N.; Garrido-Méndez, A.; Matus-Castillo, C.; Álvarez, C.; Díaz-Martínez, X.; Salas-Bravo, C.; Martínez-Sanguinetti, M.A.; et al. Auto reporte de la velocidad de marcha y su asociación con marcadores de adiposidad y riesgo cardiovascular en Chile. Rev. Med. Chile 2020, 148, 459–468. [Google Scholar] [CrossRef] [PubMed]
  52. Reyes-Molina, D.; Alonso-Cabrera, J.; Nazar, G.; Parra-Rizo, M.A.; Zapata-Lamana, R.; Sanhueza-Campos, C.; Cigarroa, I. Association between the physical activity behavioral profile and sedentary time with subjective well-being and mental health in chilean university students during the COVID-19 Pandemic. Int. J. Environ. Res. Public Health 2022, 19, 2107. [Google Scholar] [CrossRef] [PubMed]
  53. Ammar, A.; Brach, M.; Trabelsi, K.; Chtourou, H.; Boukhris, O.; Masmoudi, L.; Bouaziz, B.; Bentlage, E.; How, D.; Ahmed, M.; et al. Effects of COVID-19 home confinement on eating behaviour and physical activity: Results of the ECLB-COVID19 international online survey. Nutrients 2020, 12, 1583. [Google Scholar] [CrossRef] [PubMed]
  54. Xiao, Y.; Becerik-Gerber, B.; Lucas, G.; Roll, S.C. Impacts of working from home during COVID-19 pandemic on physical and mental well-being of office workstation users. J. Occup. Environ. Med. 2021, 63, 181–190. [Google Scholar] [CrossRef] [PubMed]
  55. Hernández-Jaña, S.; Escobar-Gómez, D.; Cristi-Montero, C.; Castro-Piñero, J.; Rodríguez-Rodríguez, F. Changes in active behaviours, physical activity, sedentary time, and physical fitness in chilean parents during the COVID-19 pandemic: A retrospective study. Int. J. Environ. Res. Public Health 2022, 19, 1846. [Google Scholar] [CrossRef]
  56. Parra-Soto, S.; Pell, J.P.; Celis-Morales, C.; Ho, F.K. Absolute and relative grip strength as predictors of cancer: Prospective cohort study of 445 552 participants in UK Biobank. J. Cachexia Sarcopenia Muscle 2022, 13, 325–332. [Google Scholar] [CrossRef]
  57. Vásquez-Gómez, J.A.; Matus-Castillo, C.; Petermann-Rocha, F.; Concha-Cisternas, Y.; Leiva, A.M.; Martínez-Sanguinetti, M.A.; Troncoso-Pantoja, C.; Garrido-Mendez, A.; Díaz-Martínez, X.; Salas, C.; et al. Caracterización de los estilos de vida en dueñas de casa chilenas. Análisis de la encuesta nacional de salud 2009–2010. Rev. Med. Chile 2019, 147, 1146–1155. [Google Scholar] [CrossRef] [Green Version]
Figure 1. Flow diagram of actions.
Figure 1. Flow diagram of actions.
Ijerph 19 06856 g001
Table 1. Sample characteristics.
Table 1. Sample characteristics.
VariablesTotal (557)Male (256)Female (301)p-Value (a)
MeanSDCIMean SDCIMeanSDCI
Age (years)28.99.728.1; 29.8289.326.8; 29.129.810.128.6; 30.90.0166 t
Weight (kg)71.713.170.6; 72.877.613.176; 79.266.610.865.4; 67.80.0001 k
Height (cm)166.78.7166; 167.5173.56.4172.7; 174.31616160.3; 161.70.0001 k
BMI (kg/m2)25.73.725.3; 2625.73.625.2; 26.125.63.825.2; 26.10.5636 t
BMI,n(%) 0.333 x2
Normal280 (50.3)--46.1; 54.4123 (48.1)--41.9; 54.1157 (52.2)--46.4; 57.7
Overweight/Obese277 (49.7)--45.5; 53.8133 (51.9)--45.8; 58144 (47.8)--42.2; 53.5
V ˙ O2max (L/min)2.480.712.42; 2.543.120.523; 3.181.930.241.91; 1.960.0001 k
V ˙ O2max (mL/kg/min)34.46.433.8; 34.940.23.639.8; 40.729.43.629; 29.80.0001 k
V ˙ O2max, n (%) 0.08 x2
Low, very low, or normal479 (86)--82.8; 88.6213 (83.2)--78; 87.3266 (88.4)--84.2; 91.5
Good, excellent or higher78 (14)--11.3; 17.143 (16.8)--12.6; 21.935 (11.6)--8.4; 15.7
Sitting (hours)63.35.7; 6.35.63.45.2; 5.96.33.46; 6.70.0021 k
Area,n(%) 0.62 x2
Urban 492 (88.3)--85.3; 90.7228 (89.1)--84.5; 92.3264 (87.7)--83.4; 90.9
Rural 65 (11.7)--9.2; 14.628 (10.9)--7.6; 15.437 (12.3)--9; 16.5
Vaccine 1,n(%) 0.965 x2
Yes453 (81.3)--77.8; 84.3208 (81.3)--75.9; 85.5245 (81.4)--76.5; 85.4
No104 (18.7)--15.6; 22.148 (18.7)--14.4; 2456 (18.6)--14.5; 23.4
Vaccine brand, n (%) <0.001 f
SINOVAC281 (63)--58.4; 67.3114 (55.6)--48.7; 62.2167 (69.3)--63.1; 74.8
PFIZER128 (28.7)--24.6; 3367 (32.7)--26.5; 39.461 (25.3)--20.1; 31.2
CANSINO23 (5.2)--3.4; 7.610 (4.9)--2.6; 8.813 (5.4)--3.1. 9
ASTRAZENECA14 (3.1)--1.8; 5.214 (6.8)--4; 11.20--0.0; 0.0
Vaccine 2,n(%) 0.078 x2
Yes319 (69.2)--64.8; 73.2138 (65.1)--58.4; 71.2181 (72.7)--66.7; 77.8
No142 (30.8)--26.7; 35.174 (34.9)--28.7; 41.568 (27.3)--22.1; 33.2
PCR,n(%) 0.03x2
Yes319 (57.3)--53.1; 61.3134 (52.3)--46.2; 58.4185 (61.5)--55.8; 66.8
No238 (42.7)--38.6; 46.8122 (47.7)--41.5; 53.8116 (38.5)--33.1; 44.1
PCR results,n(%) 0.816 x2
Negative290 (89)--85; 91.9123 (88.5)--81.9; 92.8167 (89.3)--83.9; 93
Positive36 (11)--8; 14.916 (11.5)--7.1; 21820 (10.7)--6.9; 16
Smoker,n(%) 0.286 x2
Current smoker119 (21.4)--18.1; 24.953 (20.7)--16.1; 26.166 (21.9)--17.5; 26.9
Former smoker110 (19.7)--16.6; 23.244 (17.2)--13; 22.366 (21.9)--17.5; 26.9
Never smoked328 (58.9)--54.7; 62.9159 (62.1)--55.9; 67.8169 (56.2)--50.4; 61.6
Walking pace,n(%) 0.039 f
Slow23 (4.1)--2.7; 6.15 (1.9)--0.8; 4.618 (5.9)--3.7; 9.3
Normal352 (63.2)--59; 67.1161 (62.9)--56.7; 68.6191 (63.5)--57.8; 68.7
Hurried182 (32.7)--28.8; 36.690 (35.2)--29.5; 41.292 (30.6)--25.6; 36
PA practice,n(%) <0.001x2
Does not practice144 (25.9)--22.3; 29.642 (16.4)--12.3; 21.4102 (33.9)--28.7; 39.4
Yes, < 4 times/month63 (11.3)--8.9; 14.227 (10.6)--7.3; 14.936 (12)--8.7; 16.1
Yes, 1–2 times/week148 (26.6)--23; 30.461 (23.8)--18.9; 29.487 (28.9)--24; 34.3
Yes, ≥ 3 times/week202 (36.2)--32.3; 40.3126 (49.2)--43.1; 55.376 (25.2)--20.6; 30.4
High pressure,n(%) 0.189 x2
No, they never told me446 (80.1)--76.5; 83.1202 (78.9)--73.4; 83.4244 (81.1)--76.2; 85.1
Yes, one time53 (9.5)--7.3; 12.230 (11.7)--8.3; 16.223 (7.6)--5.1; 11.2
Yes, more than once35 (6.3)--4.5; 8.612 (4.7)--2.6; 823 (7.6)--5.1; 11.2
I don’t remember, I’m not sure23 (4.1)--2.7; 6.112 (4.7)--2.6; 811 (3.7)--2; 6.4
Diabetes,n(%) 0.019 f
No515 (94.5)--92.2; 96.1245 (96.8)--93.7; 98.4270 (92.5)--88.8; 94.9
Yes30 (5.5)--3.8; 7.78 (3.2)--1.5; 6.222 (7.5)--5; 11.1
High cholesterol, n (%) 0.067 f
No, they never told me434 (77.9)--74.2; 81.1207 (80.9)--75.5; 85.2227 (75.4)--70.2; 79.9
Yes, one time69 (12.4)--9.8; 15.433 (12.9)--9.2; 17.636 (12)--8.7; 16.1
Yes, more than once35 (6.3)--4.5; 8.69 (3.5)--1.8; 6.626 (8.6)--5.9; 12.4
I don’t remember, I’m not sure19 (3.4)--2.1; 5.27 (2.7)--1.3; 5.612 (4)--2.2; 6.9
Heart attack, n(%) 0.711 f
No541 (99.6)--98.5; 99.9250 (99.6)--97.2; 99.9291 (99.7)--97.5; 99.9
Yes 2 (0.4)--0.09; 1.41 (0.4)--0.05; 2.71 (0.3)--0.04; 2.4
Vascular accident or cerebral thrombus,n(%) 0.448 f
No543 (99.5)--98.3; 99.8252 (99.2)--96.8; 99.8291 (99.7)--97.5; 99.9
Yes3 (0.5)--0.1; 1.62 (0.8)--0.1; 3.11 (0.3)--0.05; 2.4
(a): the difference between male and female; BMI: body mass index; CI: confidence interval; f: Fisher’s exact test; k: Kruskal–Wallis test; PA: physical activity; PCR: Polymerase Chain Reaction; SD: standard deviation; t: Student’s t-test; u: Mann–Whitney U test; V ˙ O2max: maximum oxygen consumption; x2; Chi-square.
Table 2. Probability of changes in V ˙ O2max * due to control of COVID-19.
Table 2. Probability of changes in V ˙ O2max * due to control of COVID-19.
VariableORCI (95%)p-Value
Vaccine 1 (yes)0.520.29; 0.950.019
Vaccine 2 (yes)0.330.18; 0.590.0001
PCR (yes)0.660.40; 1.110.099
PCR (−) 0.620.22; 1.960.32
PCR (+)1.610.51; 4.340.32
CI: confidence interval; OR: odds ratio; PCR: polymerase chain test reaction; (−): negative; (+): positive. * mL/kg/min.
Table 3. COVID-19 control variables that predict absolute V ˙ O2max.
Table 3. COVID-19 control variables that predict absolute V ˙ O2max.
Variableβp-ValueCI 95%
V ˙ O2max (L/min) Vaccine first
Model 1 −0.040.587−0.19; 0.11
Model 2−0.080.251−0.22; 0.05
Model 3−0.030.643−0.18; 0.11
Model 4−0.010.85−0.16; 0.13
Model 5−0.030.669−0.19; 0.12
Model 6−0.0050.948−0.16; 0.15
V ˙ O2max (L/min) Vaccine second
Model 1 −0.130.059−0.27; 0.005
Model 2−0.24<0.001−0.37; −0.11
Model 3−0.10.173−0.24; 0.04
Model 4−0.120.072−0.27; 0.01
Model 5−0.110.144−0.26; 0.03
Model 6−0.080.288−0.23; 0.07
V ˙ O2max (L/min) PCR
Model 1 −0.040.508−0.16; 0.07
Model 2−0.060.276−0.17; 0.05
Model 3−0.030.559−0.15; 0.08
Model 4−0.030.564−0.15; 0.08
Model 5−0.050.428−0.17; 0.07
Model 6−0.040.522−0.16; 0.08
V ˙ O2max (L/min) PCR (−)
Model 1 −0.190.132−0.44; 0.05
Model 2−0.130.266−0.36; 0.11
Model 3−0.170.169−0.43; 0.07
Model 4−0.20.119−0.45; 0.05
Model 5−0.160.204−0.42; 0.09
Model 6−0.160.205−0.42; 0.09
CI: confidence interval; PCR: polymerase chain reaction; V ˙ O2max: maximum oxygen consumption; mL/kg/min: milliliters/kilogram/minute; (–): negative. Note: Model 1 is not adjusted. Model 2 is adjusted by BMI. Model 3 is adjusted by region, area of residence, educational level, marital status, and occupational situation. Model 4 adjusted for smoking habit, walking pace, monthly physical activity, and sitting time. Model 5 is adjusted for hypertension, diabetes, high cholesterol, heart attack, vascular accident, and cerebral thrombosis. Model 6 was adjusted by models 2, 3, 4, and 5.
Table 4. COVID-19 control variables that predict the relative V ˙ O2max.
Table 4. COVID-19 control variables that predict the relative V ˙ O2max.
Variableβp-ValueCI 95%
V ˙ O2max (mL/kg/min) Vaccine first
Model 1−1.680.017−3.06; −0.30
Model 2−1.370.044−2.71; −0.03
Model 3−1.820.009−3.18; −0.46
Model 4−1.090.106−2.42; 0.23
Model 5−1.30.062−2.68; 0.06
Model 6−1.150.094−2.5; 0.19
V ˙ O2max (mL/kg/min) Vaccine second
Model 1−3.44<0.001−4.68; −2.20
Model 2−2.92<0.001−4.15; −1.69
Model 3−3.05<0.001−4.30; −1.79
Model 4−3.28<0.001−4.48; −2.08
Model 5−2.92<0.001−4.19; −1.66
Model 6−2.54<0.001−3.8; −1.28
V ˙ O2max (mL/kg/min) PCR
Model 1−0.890.106−1.99; 0.19
Model 2−0.730.173−1.78; 0.32
Model 3−0.80.142−1.87; 0.26
Model 4−0.660.210−1.71; 0.37
Model 5−0.940.090−2.03; 0.14
Model 6−0.630.237−1.68; 0.41
V ˙ O2max (mL/kg/min) PCR (-)
Model 1−1.240.263−3.43; 0.93
Model 2−1.490.173−3.65; 0.66
Model 3−0.910.413−3.11; 1.28
Model 4−1.460.174−3.56; 0.64
Model 5−0.920.398−3.07; 1.2
Model 6−0.930.387−3.05; 1.18
CI: confidence interval; PCR: polymerase chain reaction; V ˙ O2max: maximum oxygen consumption; mL/kg/min: milliliters/kilogram/minute; (–): negative. Note: Model 1 is not adjusted. Model 2 is adjusted by BMI. Model 3 is adjusted by region, area of residence, educational level, marital status, and occupational situation. Model 4 adjusted for smoking habit, walking pace, monthly physical activity, and sitting time. Model 5 is adjusted for hypertension, diabetes, high cholesterol, heart attack, vascular accident, and cerebral thrombosis. Model 6 was adjusted by models 2, 3, 4, and 5.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Vásquez-Gómez, J.; Faúndez-Casanova, C.; Souza de Carvalho, R.; Castillo-Retamal, F.; Valenzuela Reyes, P.; Concha-Cisternas, Y.; Luna-Villouta, P.; Álvarez, C.; Godoy-Cumillaf, A.; Hernández-Mosqueira, C.; et al. Estimated Oxygen Consumption with the Abbreviated Method and Its Association with Vaccination and PCR Tests for COVID-19 from Socio-Demographic, Anthropometric, Lifestyle, and Morbidity Outcomes in Chilean Adults. Int. J. Environ. Res. Public Health 2022, 19, 6856. https://doi.org/10.3390/ijerph19116856

AMA Style

Vásquez-Gómez J, Faúndez-Casanova C, Souza de Carvalho R, Castillo-Retamal F, Valenzuela Reyes P, Concha-Cisternas Y, Luna-Villouta P, Álvarez C, Godoy-Cumillaf A, Hernández-Mosqueira C, et al. Estimated Oxygen Consumption with the Abbreviated Method and Its Association with Vaccination and PCR Tests for COVID-19 from Socio-Demographic, Anthropometric, Lifestyle, and Morbidity Outcomes in Chilean Adults. International Journal of Environmental Research and Public Health. 2022; 19(11):6856. https://doi.org/10.3390/ijerph19116856

Chicago/Turabian Style

Vásquez-Gómez, Jaime, César Faúndez-Casanova, Ricardo Souza de Carvalho, Franklin Castillo-Retamal, Pedro Valenzuela Reyes, Yeny Concha-Cisternas, Pablo Luna-Villouta, Cristian Álvarez, Andrés Godoy-Cumillaf, Claudio Hernández-Mosqueira, and et al. 2022. "Estimated Oxygen Consumption with the Abbreviated Method and Its Association with Vaccination and PCR Tests for COVID-19 from Socio-Demographic, Anthropometric, Lifestyle, and Morbidity Outcomes in Chilean Adults" International Journal of Environmental Research and Public Health 19, no. 11: 6856. https://doi.org/10.3390/ijerph19116856

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop